



**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffery T. Helvey\*  
Leidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Vincent L. Capuano  
Kendrick P. Patterson  
Albert J. Fasulo II\*  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono\*  
Virgil Lee Beaston\*  
Reginald D. Lucas\*  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham\*  
Christine M. Lhullier  
Rae Lynn Pregelman\*  
Jane Shershenovich\*  
Lawrence J. Carroll\*

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III

Registered Patent Agents  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas

July 17, 2002

**WRITER'S DIRECT NUMBER:**  
(202) 371-2625

**INTERNET ADDRESS:**  
ESTEFFE@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Art Unit 1651

Re: U.S. Utility Patent Application  
Appl. No. 09/881,204; Filed: June 15, 2001  
For: **Pluripotent Mammalian Cells**  
Inventors: Page *et al.*  
Our Ref: 1954.0010001/EKS/PSC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF Cover Letter;
2. Information Disclosure Statement;
3. Form PTO-1449 (citing 3 documents - 1 page);
4. 3 cited documents (AR1, AS1, and AT1); and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.


**RECEIVED**  
JUL 18 2002  
TECH CENTER 1600/2900

Commissioner for Patents  
July 17, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

Enclosures

::ODMA\MHODMA\SKGF\_DC1;35392;1  
SKGF Rev. 2/15/02 dcw

#6  
DLO  
7/19/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Page *et al.*

Appl. No. 09/881,204

Filed: June 15, 2001

For: **Pluripotent Mammalian Cells**

Confirmation No. 5122

Art Unit: 1651

Examiner: *To Be Assigned*

Atty. Docket: 1954.0010001/EKS/PSC

**Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:-

RECEIVED  
JUL 18 2002  
TECH CENTER 1600/2900

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

Date: 7/17/02

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600